Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

6.730 -0.210 (-3.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	390,887
Open	6.930
Bid (Size)	6.710 (900)
Ask (Size)	6.720 (2,900)
Prev. Close	6.940
Today's Range	6.680 - 7.000
52wk Range	2.315 - 15.74
Shares Outstanding	61,758,994
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

Performance

YTD	-38.4%	-38.4%
1 Month	-25.1%	-25.1%
3 Month	-41.9%	-41.9%
6 Month	-23.9%	-23.9%
1 Year	+117.8%	+117.8%

More News

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

March 19, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics (NASDAQ:FULC) Q4 2025 Earnings: Pociredir Data Steals Spotlight Amid In-Line Financials ↗

February 24, 2026

Via Chartmill

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

March 03, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

February 24, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 24, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

February 17, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

December 10, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active

December 09, 2025

Via AB Newswire

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

December 08, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 08, 2025

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 08, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

December 08, 2025

Via Chartmill

Fulcrum Stock Nears March 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes ↗

December 08, 2025

Via Stocktwits

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

December 02, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 18, 2025

Via Benzinga

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?

Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?

Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?

The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market

What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?

The current price of Fulcrum Therapeutics, Inc. - Common Stock is 6.730

When was Fulcrum Therapeutics, Inc. - Common Stock last traded?

The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 03/27/26 04:00 PM ET

What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?

The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 415.64M

How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?

Fulcrum Therapeutics, Inc. - Common Stock has 416M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.